Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.
European Neuropsychopharmacology March 1, 2024 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B Silva et al. 25 citations
Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at...
DOI: 10.1016/j.euroneuro.2023.12.006 (opens in new tab)
Full text (opens in new tab)
Entheogens
Clinical trial
Dose-response study
Mood disorders
+6